Proteostasis Asks FDA to Help It Advance PTI-808 as Cystic Fibrosis Combo Treatment

Proteostasis Asks FDA to Help It Advance PTI-808 as Cystic Fibrosis Combo Treatment
0
(0)

Proteostasis Therapeutics has filed an Investigational New Drug application with the U.S. Food and Drug Administration for PTI-808 as a treatment for cystic fibrosis.

PTI-808 promotes the activity of the cystic fibrosis transmembrane conductance regulator, or CFTR, the protein that is faulty in CF. Scientists call the drug a potentiator because its designed to bolster CFTR’s  activity.

Proteostasis Therapeutics developed PTI-808 as a component of a triple combination treatment for CF.

The company plans a Phase 2 clinical trial of PTI-808 in healthy individuals in July of 2018. It also plans a Phase 1 trial with CF patients carrying the F508del mutation of the CFTR gene. That study will cover patients who are not receiving Orkambi (lumacaftor/ivacaftor).

“While potentiators are an established part of CF therapy, there remains significant room for improvement in this critical component of therapy, and we believe PTI-808, with a potential once-a-day dosing regimen, offers the potential to fill this gap,” Meenu Chhabra, Proteostasis Therapeutics’ president and CEO, said in a press release.

“Each component of our potential triple combination therapy is now clinical [trial] stage, with active and ongoing clinical development programs for both PTI-428, an amplifier, and PTI-801, a new-generation corrector,” Chhabra added. A corrector helps increase the functionality of the CFTR protein.

Proteostasis is in the midst of conducting an ongoing Phase 1 clinical trial of PTI-801 in healthy individuals.

It is also doing a study on another of its therapies, PTI-428. That research involves investigating PTI-428, alone or combined with Orkambi, as a cystic fibrosis treatment. The team will compare results from the two treated groups with those of patients receiving a control therapy — either a placebo and Orkambi, or a placebo alone.

If the findings of both studies are promising, Proteostasis plans a dose-escalating study with CF patients with the F508del mutation who have not been treated with Orkambi. In this study, patients will receive PTI-428 and PTI-801 in a triple combination known as PTI-NC-733.

“With the filing of an IND [Investigational New Drug application] for the potentiator PTI-808, the third and final piece of our triple combination, we have reached an important milestone in assembling PTI-NC-733 [the triple combination therapy],” Chhabra said. “Pending positive results from ongoing clinical trials with PTI-428 and PTI-801, we expect to initiate a trial combining all three proprietary CFTR modulators before the end of 2017.”

 

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?